Humacyte, Inc. (HUMA) is a medical technology company that has sparked innovative thought in the field of regenerative medicine. Founded in 2004 and based in Durham, North Carolina, Humacyte primarily focuses on the research, development, and commercialization of bioengineered human acellular vessels (HAVs) that can be utilized across multiple therapeutic applications.
The flagship product of Humacyte is HUMACYL, a bioengineered blood vessel that is designed to provide vascular access for patients undergoing hemodialysis - a treatment typically required for those with advanced kidney disease. The development of HUMACYL represents a significant revolution in regenerative medicine as it has the potential to overcome many of the current hindrances related to vascular grafts, such as graft failures and infections.
Moreover, the company's innovative technology platform uses the proprietary process of seeding a degradable scaffold with smooth muscle cells, which are subsequently decellularized to retain an extracellular matrix-based structure. This gives rise to products that are off-the-shelf, immunologically inert, non-thrombogenic, and capable of self-healing.
Humacyte, being a research-oriented organization, is also involved in the research and development of additional HAVs for other complex medical conditions including peripheral arterial disease, vascular trauma, and pediatric heart surgery.
Under the leadership of CEO Dr. Laura Niklason, Humacyte has demonstrated the potential to revolutionize the landscape of regenerative medicine. Recognizing the company's achievements, it was awarded the “Technology Pioneer” award by the World Economic Forum in 2017. Moreover, it has been able to raise funds from renowned life science investors, further emphasizing the significant potential seen in Humacyte's regenerative solutions.
The company's dedication to research and innovation, combined with its mission to change the medical landscape, make Humacyte a key player in the regenerative medicine sphere. With a clear focus on improving patient outcomes and a strong pipeline of bioengineered tissues, Humacyte is poised to make a substantial impact on regenerative medicine.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Humacyte reported a Q3 2026 earnings beat, with a loss of $0.06 per share against an expected $0.09, and revenue up 36.5% year-over-year to $1.0 million, driven by strong sequential growth in its Symvess vascular graft product. While the company remains unprofitable with negative gross margins, the significant acceleration in commercial adoption suggests potential market penetration. Investors are closely watching for sustained hospital adoption and improvements in manufacturing scale to achieve positive gross margins, which are critical for future profitability.
Humacyte, Inc. announced its Q3 2026 financial results, reporting a narrower-than-expected loss of $0.06 per share, beating analyst estimates. The company's revenue increased by 36.5% year-over-year to $1.0 million, driven by the commercial rollout and gradual uptake of its Symvess vascular graft product in 49 hospitals. Despite a net loss of $15.5 million due to expansion investments, analyst sentiment remains positive with a consensus of 6 buys and 2 holds.
Humacyte, Inc. announced its Q3 2026 financial results, reporting a narrower-than-expected loss of $0.06 per share, surpassing analyst estimates by 33.3%. The company's revenue reached $1.0M, a 36.5% increase year-over-year, driven by the commercial rollout of its Symvess vascular graft product. Humacyte continues to expand the adoption of its bioengineered tissues, with 49 hospitals ordering Symvess during the quarter.
Humacyte reported a 151% increase in Synvest sales for Q3 2026, reaching over $1 million, and expects to double sales in Q4. The company is preparing to submit a supplemental Biologics License Application (sBLA) for its ATEV product for dialysis access and has initiated a Phase 2a clinical study for Coronary Tissue Engineered Vessels (CTEV) for coronary artery bypass grafting. Despite a net loss of $15.5 million in Q3 2026, Humacyte saw an improvement from the previous year and is optimistic about future growth driven by its commercial strategy and pipeline progress.
HUMACYTE ($HUMA) announced its Q3 2026 earnings, reporting -$0.07 per share, surpassing estimates of -$0.09. The company also beat revenue estimates with $1,030,000. The article details recent insider trading activity, with more purchases than sales, and provides an overview of institutional investor movements and analyst price targets for the stock.
Humacyte, Inc. (HUMA) shares fell by 12.11% in the latest trading session, underperforming the broader S&P 500's 4.36% loss. The company is set to announce its earnings on November 10, 2026, with projected EPS of -$0.09 and revenue of $0.86 million, indicating significant growth from the previous year. Despite recent declines, the stock holds a Zacks Rank of #3 (Hold), and its industry ranks in the top 45% of all industries.